A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events
← catalyst calendarNCT07474649 · readout in 652 d
Sponsored by Daiichi Sankyo (industry) · 4568.T — their whole pipeline →.
Phase
Phase 3
Status
Not yet recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
103estimated
Sites
12
Countries
Germany, Italy, Spain
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-08-15 | estimated | When the study began enrolling |
| Primary completion | 2028-06-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-10-02 | estimated | The whole study's end, after follow-up |
| First posted | 2026-03-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Coronary Atherosclerosis
- Mixed Dyslipidemia
- Hypercholesterolemia
Interventions
- Drug: Bempedoic acid
- Drug: Ezetimibe
- Drug: Rosuvastatin
- Drug: Atorvastatin
Primary outcome
what the primary-completion date above is the date OFAnnualised change in percentage plaque burden (Δ%PB)
measured Baseline up to 12 months
Permalink · 4568.T's whole pipeline · Catalyst calendar · Every registered study · What changed